In choose which will deliver you to discoveries, the research watched around 58 people with the use of type 1 diabetes.
Advertisement
The trials are described in one paper in the New England Journal of Medicine and were reported at the European Association for the Study of Diabetes Annual Meeting in Stockholm.
The 33 adults used the system day and night, and 25 children and teens in the study used it overnight.
Still, scientists say the results underline the need for people with diabetes to monitor their blood-sugar levels closely and for physicians to actively treat diabetes patients even as cognitive functions decline.
An artificial pancreas given to children and adults with type 1 diabetes going about their daily lives has been proven to work for 12 weeks – meaning the technology, developed at the University of Cambridge, can now offer a whole school term of extra freedom for children with the condition. “We did not restrict participants’ dietary intake or, after the initial 2 weeks, physical activity or geographical movements”.
Type 1 diabetes is an autoimmune disorder characterized by the pancreas producing too little or no insulin for the body.
Scientists have previously suggested a link between elevated blood-sugar levels and Alzheimer’s disease, but the researchers said this was the first large-scale study looking at how controlling the presence of glucose in the blood affected the risk of being diagnosed with dementia in the future. For many years, researchers have pursued development of a so-called “artificial pancreas” that would free patients from the constant need to monitor blood sugar levels; this would represent not only a huge step forward in health maintenance, but also quality of life. Patients received treatment with an “artificial beta cell”, otherwise known as a closed-loop artificial pancreas, for a 12-week period, and treatment with a sensor-augmented insulin pump for a similar period.
Advertisement
The adults’ glucose levels stayed within their target ranges 68 percent of the time when using the closed-loop system, as opposed to 57 percent of the time when patients were monitoring and dosing themselves. “The closed-loop system differs from conventional pump therapy and threshold-suspend approaches in that it uses a control algorithm that autonomously and continually increases and decreases the subcutaneous delivery of insulin on the basis of real-time sensor glucose levels”. One adolescent had two episodes of hypoglycemic seizures, but the artificial pancreas, called the “closed-loop system” by the researchers, was not turned on at the time.
